← Back to Screener
Xenetic Biosciences, Inc. (XBIO)
Price$3.31
Value ScoreA
Growth ScoreB
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)20.43%
Price vs S&P 500 (4W)1.09%
VGM Score76.79
Market Capitalization$7.22M
All Metrics
Book Value / Share (Quarterly)$3.03
P/TBV (Annual)1.46x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)20.29%
Cash Flow / Share (Quarterly)$-0.79
Price vs S&P 500 (YTD)34.23%
Gross Margin (TTM)98.68%
Net Profit Margin (TTM)-70.03%
EPS (TTM)$-1.24
10-Day Avg Trading Volume0.01M
EPS Excl Extra (TTM)$-1.24
Revenue Growth (5Y)46.57%
EPS (Annual)$-1.58
ROI (Annual)-36.25%
Gross Margin (Annual)97.89%
Net Profit Margin (5Y Avg)-256.27%
Cash / Share (Quarterly)$3.20
Revenue Growth QoQ (YoY)36.01%
ROA (Last FY)-32.05%
Revenue Growth TTM (YoY)23.52%
EBITD / Share (TTM)$-1.27
ROE (5Y Avg)-44.62%
Operating Margin (TTM)-75.05%
Cash Flow / Share (Annual)$-1.00
P/B Ratio1.04x
P/B Ratio (Quarterly)0.88x
Net Income / Employee (Annual)$-1,340,400
EV / Revenue (TTM)-0.04x
Net Interest Coverage (TTM)-4.23x
ROA (TTM)-33.48%
EPS Incl Extra (Annual)$-1.58
Current Ratio (Annual)8.32x
Quick Ratio (Quarterly)7.67x
3-Month Avg Trading Volume0.02M
52-Week Price Return5.70%
Revenue / Employee (TTM)$1,595,000
Tangible BV / Share (Quarterly)$14.05
P/S Ratio (Annual)2.42x
Asset Turnover (Annual)0.36x
52-Week High$13.93
Operating Margin (5Y Avg)-265.97%
EPS Excl Extra (Annual)$-1.58
Tangible BV CAGR (5Y)75.69%
26-Week Price Return36.36%
Quick Ratio (Annual)8.14x
13-Week Price Return30.17%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)7.93x
Enterprise Value$-130,400
Revenue / Share Growth (5Y)20.54%
Asset Turnover (TTM)0.48x
Book Value / Share Growth (5Y)-25.48%
Revenue / Employee (Annual)$1,488,200
Pretax Margin (Annual)-90.07%
Cash / Share (Annual)$3.44
3-Month Return Std Dev77.43%
Net Income / Employee (TTM)$-1,117,000
ROE (Last FY)-36.25%
Net Interest Coverage (Annual)-22.81x
EPS Basic Excl Extra (Annual)$-1.58
P/FCF (TTM)1.42x
Receivables Turnover (TTM)5.06x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.24
Receivables Turnover (Annual)5.06x
ROI (TTM)-39.28%
P/S Ratio (TTM)2.26x
Pretax Margin (5Y Avg)-256.27%
Revenue / Share (Annual)$1.75
Tangible BV / Share (Annual)$14.05
Price vs S&P 500 (52W)-22.50%
Year-to-Date Return45.16%
5-Day Price Return3.99%
EPS Normalized (Annual)$-1.58
ROA (5Y Avg)-40.29%
Net Profit Margin (Annual)-90.07%
Month-to-Date Return3.96%
Cash Flow / Share (TTM)$-2.92
EBITD / Share (Annual)$-1.67
Operating Margin (Annual)-95.23%
ROI (5Y Avg)-44.62%
EPS Basic Excl Extra (TTM)$-1.24
P/TBV (Quarterly)1.46x
P/B Ratio (Annual)0.67x
Pretax Margin (TTM)-70.03%
Book Value / Share (Annual)$3.23
Price vs S&P 500 (13W)20.42%
Beta2.21x
P/FCF (Annual)4.88x
Revenue / Share (TTM)$1.39
ROE (TTM)-39.28%
52-Week Low$1.90
vGradeA
gGradeB
mGradeB
vgmGradeB
Show chart for
Analyst Recommendations
Nov 2025
Dec 2025
Jan 2026
Feb 2026
2.17
2.17
2.17
2.17
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
XBIOXenetic Biosciences, Inc. | A | B | B | $3.31 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Xenetic Biosciences Inc is a biopharmaceutical company developing DNase-based therapies for difficult-to-treat cancers. The company's proprietary DNase technology targets neutrophil extracellular traps (NETs) to enhance the effectiveness of existing cancer treatments and immunotherapies. Xenetic is advancing a systemic DNase program as an adjunctive therapy for pancreatic cancer and other metastatic solid tumors.